[Diurnal rhythm of endogenous somatostatin in patients with carcinoid].
OBJECTIVE
Was to investigate the differences of the circadian rhythm of the endogenous somatostatin in patients with carcinoid and in healthy probands.


METHODS
The group of 30 patients (16 men/14 women) was divided onto two groups. The group M of 20 (12/8) pts with metastatic disease and group B of 10 pts without known metastases at the time of investigation. The control group A included by 12 healthy probands (7/5). Plasma levels of somatostatin were determined by radioimmunoassay. Fisher periodogram and Halberg's cosinor were used for statistical evaluation.


RESULTS
We confirmed the 24-hour circadian rhythm of somatostatin in group A, B and M. Patients of the M group when compared with A and B groups had higher mesor and the later 24-hour acrophase (p < 0.05) and 12-hour acrophase (p < 0.05). Treatment with lanreotide led to the significant decrease of the somatostatin mesor (p < 0.05).
Kinová
S
S
I. interná klinika LF UK, Bratislava Nemocnica Ministerstva unútra SR, Bratislava.
Kovácová
E
E
Kratochvíĺová
E
E
Ondrejka
P
P
Duris
I
I
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000097:blood* / Q000188:drug therapy; D002940:Circadian Rhythm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000097:blood* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin
Diurnálny rytmus endogénneho somatostatínu u pacientov s karcinoidom.